Hologic (NSDQ:HOLX) announced that it completed its previously announced acquisition of Biotheranostics for $230 million. Marlborough, Mass.-based Hologic last month announced that it was set to buy Biotheranostics and its two molecular diagnostic tests for breast and metastatic cancers, the Breast Cancer Index and CancerTYPE ID. Both laboratory-developed tests are not required to be cleared by […]
bioTheranostics
Hologic to acquire Biotheranostics for $230M
Hologic (NSDQ:HOLX) announced that it agreed to acquire molecular diagnostic test maker Biotheranostics for approximately $230 million. Privately held, commercial-stage Biotheranostics provides molecular diagnostics for breast and metastatic cancers. Both of its tests are PCR-based gene expression tests which have been validated in large studies in areas of oncology with unmet needs and high growth potential, […]
Delcath to pare 20% of its U.S. workforce | Personnel Moves
Queensbury, N.Y.-based Delcath (NSDQ:DCTH) announced last week that it plans to pare its workforce by about 20%, the latest in a series of layoff announcements from the oncology devices maker. This is the 3rd time this year that Delcath has announced imminent layoffs, having announced smaller cuts in April and larger layoffs in January.
